These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

48 related articles for article (PubMed ID: 19594323)

  • 1. Impact of neutropenic complications on short-term disability in patients with cancer receiving chemotherapy.
    Song X; Fowler R; Ruiz K; Hurley D; Barron RL
    J Med Econ; 2009 Jun; 12(2):154-63. PubMed ID: 19594323
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Costs of asthma among US working adults.
    Shenolikar R; Song X; Anderson JA; Chu BC; Cantrell CR
    Am J Manag Care; 2011 Jun; 17(6):409-16. PubMed ID: 21756011
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluating the total costs of chemotherapy-induced febrile neutropenia: results from a pilot study with community oncology cancer patients.
    Bennett CL; Calhoun EA
    Oncologist; 2007 Apr; 12(4):478-83. PubMed ID: 17470690
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Estimating the cost of cancer: results on the basis of claims data analyses for cancer patients diagnosed with seven types of cancer during 1999 to 2000.
    Chang S; Long SR; Kutikova L; Bowman L; Finley D; Crown WH; Bennett CL
    J Clin Oncol; 2004 Sep; 22(17):3524-30. PubMed ID: 15337801
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Neutropenic complications in advanced-stage non-Hodgkin's lymphoma: implications for the use of prophylactic recombinant human granulocyte-colony stimulating factor (G-CSF).
    Bobey N; Woodman RC
    Clin Invest Med; 1998 Apr; 21(2):63-70. PubMed ID: 9562926
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impact of neutropenia on delivering planned chemotherapy for solid tumours.
    Khan S; Dhadda A; Fyfe D; Sundar S
    Eur J Cancer Care (Engl); 2008 Jan; 17(1):19-25. PubMed ID: 18181887
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Risk of hospitalization for neutropenic complications of chemotherapy in patients with primary solid tumors receiving pegfilgrastim or filgrastim prophylaxis: a retrospective cohort study.
    Weycker D; Malin J; Kim J; Barron R; Edelsberg J; Kartashov A; Oster G
    Clin Ther; 2009 May; 31(5):1069-81. PubMed ID: 19539108
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Risk index for predicting complications and prognosis in Thai patients with neutropenia and fever.
    Chayakulkeeree M; Thamlikitkul V
    J Med Assoc Thai; 2003 Mar; 86(3):212-23. PubMed ID: 12757060
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Retrospective cost analysis of management of febrile neutropenia in cancer patients in Spain.
    Mayordomo JI; López A; Viñolas N; Castellanos J; Pernas S; Domingo Alonso J; Frau A; Layola M; Antonio Gasquet J; Sánchez J;
    Curr Med Res Opin; 2009 Oct; 25(10):2533-42. PubMed ID: 19722781
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Incidence, cost, and mortality of neutropenia hospitalization associated with chemotherapy.
    Caggiano V; Weiss RV; Rickert TS; Linde-Zwirble WT
    Cancer; 2005 May; 103(9):1916-24. PubMed ID: 15751024
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Economic burden and co-morbidities of atrial fibrillation in a privately insured population.
    Wu EQ; Birnbaum HG; Mareva M; Tuttle E; Castor AR; Jackman W; Ruskin J
    Curr Med Res Opin; 2005 Oct; 21(10):1693-9. PubMed ID: 16238910
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Low mannose-binding lectin concentration is associated with severe infection in patients with hematological cancer who are undergoing chemotherapy.
    Vekemans M; Robinson J; Georgala A; Heymans C; Muanza F; Paesmans M; Klastersky J; Barette M; Meuleman N; Huet F; Calandra T; Costantini S; Ferrant A; Mathissen F; Axelsen M; Marchetti O; Aoun M
    Clin Infect Dis; 2007 Jun; 44(12):1593-601. PubMed ID: 17516403
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dose intensity and hematologic toxicity in older cancer patients receiving systemic chemotherapy.
    Shayne M; Culakova E; Poniewierski MS; Wolff D; Dale DC; Crawford J; Lyman GH
    Cancer; 2007 Oct; 110(7):1611-20. PubMed ID: 17705197
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pegfilgrastim administered on the same day with dose-dense adjuvant chemotherapy for breast cancer is associated with a higher incidence of febrile neutropenia as compared to conventional growth factor support: matched case-control study of the Hellenic Cooperative Oncology Group.
    Skarlos DV; Timotheadou E; Galani E; Samantas E; Grimani I; Lianos E; Aravantinos G; Xanthakis I; Pentheroudakis G; Pectasides D; Fountzilas G
    Oncology; 2009; 77(2):107-12. PubMed ID: 19622901
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The economic burden of lung cancer and the associated costs of treatment failure in the United States.
    Kutikova L; Bowman L; Chang S; Long SR; Obasaju C; Crown WH
    Lung Cancer; 2005 Nov; 50(2):143-54. PubMed ID: 16112249
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immediate vs. delayed imipenem treatment in cancer patients with profound neutropenia induced by high-dose chemotherapy: results of a randomized study.
    García-Sáenz JA; Martín M; Casado A; Pérez-Segura P; Manrique I; Flores L; Macias JA; Cámara JC; Perezagua C; Díaz-Rubio E
    Rev Esp Quimioter; 2002 Sep; 15(3):257-63. PubMed ID: 12582429
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Costs of uncontrolled chemotherapy-induced nausea and vomiting among working-age cancer patients receiving highly or moderately emetogenic chemotherapy.
    Tina Shih YC; Xu Y; Elting LS
    Cancer; 2007 Aug; 110(3):678-85. PubMed ID: 17567835
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Neutropenic events in community practices reduced by first and subsequent cycle pegfilgrastim use.
    Ozer H; Mirtsching B; Rader M; Luedke S; Noga SJ; Ding B; Dreiling L
    Oncologist; 2007 Apr; 12(4):484-94. PubMed ID: 17470691
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Chemotherapy-related myelosuppression as a marker of survival in epithelial ovarian cancer patients.
    Rocconi RP; Matthews KS; Kemper MK; Hoskins KE; Barnes MN
    Gynecol Oncol; 2008 Feb; 108(2):336-41. PubMed ID: 18006047
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Incidence and clinical impact of chemotherapy induced myelotoxicity in cancer patients: an observational retrospective survey.
    Repetto L;
    Crit Rev Oncol Hematol; 2009 Nov; 72(2):170-9. PubMed ID: 19406660
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 3.